Skip to content

Reported November 12, 2024 · Before market open

EPS-$0.24Miss by $0.08
EPS estimate-$0.16

Next report

Aug 14, 2026 (In 2 weeks)
EPS estimate-$0.17

Financials

Q3 2024

Income statement

See full
Operating income-$7.4M-63.5%
Net income-$7.1M-67.0%
EPS (diluted)-$0.24-4.3%

Balance sheet

See full
Cash & equivalents$19.7M+0.6%
Total debt$1.1M
Total equity$17.6M-11.2%
Total assets$25.1M+11.9%

Cash flow

See full
Operating cash flow-$4.0M-30.8%
CapEx$271.5K
Free cash flow-$4.3M

Valuation & ratios

Valuation

as of 09/30/24
See full
Market cap$43.84M-31.0%
Enterprise value$25.24M

Returns & leverage

See full
Return on equity-117.3%+125pp
Debt / equity0.1×
Current ratio3.5×-4.4×

Versus estimates

Ask the moment Immix Biopharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immix Biopharma, Inc. report Q3 2024 earnings?
Immix Biopharma, Inc. (IMMX) reported Q3 2024 earnings on November 12, 2024 before market open.
What were Immix Biopharma, Inc.'s Q3 2024 revenue and EPS?
Immix Biopharma, Inc. reported eps of $-0.24 for Q3 2024.
Did Immix Biopharma, Inc. beat estimates in Q3 2024?
EPS missed the consensus estimate of $-0.16 by $0.08.
Where can I find Immix Biopharma, Inc.'s Q3 2024 SEC filings?
You can read the 10-Q periodic report (0001493152-24-044787) directly on SEC EDGAR. The filing index links above go to sec.gov.